Zogenix to Release Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 6

EMERYVILLE, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter ended June 30, 2018, after the market close, and will host a corporate update conference call and webcast on Monday, August 6, 2018, at 4:30 PM Eastern Time.

Conference Call DetailsMonday, August 6th @ 4:30 PM Eastern Time/1:30 PM Pacific TimeToll Free:                     800-263-0877International:               323-794-2094Conference ID:           1390518Webcast:                     http://public.viavid.com/index.php?id=130329

Replays, Available through August 20th:Domestic:                    844-512-2921International:               412-317-6671Replay PIN:                1390518

About ZogenixZogenix, Inc. (Nasdaq: ZGNX) is a pharmaceutical company dedicated to developing therapies for people living with severe central nervous system (CNS) disorders who have limited or no treatment options. Led by a team of experts in rare disease development and CNS conditions, Zogenix is rapidly advancing the clinical investigation and development of ZX008 (fenfluramine hydrochloride) for patients with severe, rare epilepsies, including Dravet and Lennox-Gastaut syndromes.

For more information, visit www.zogenix.com.

CONTACT: Investors:Andrew McDonaldFounding Partner, LifeSci Advisors LLC646-597-6987 | [email protected]

You May Also Be Interested In

• Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
• European stocks rise, helped by positive global sentiment; NatWest gains
• Apollo Global Management (APO) to Buy US Silica (SLCA) for $15.50/sh Cash